New glaucoma drugs yield large, lasting reductions in intraocular pressure

(Mary Ann Liebert, Inc./Genetic Engineering News) Two novel ocular hypotensive agents that have just been approved for use in humans -- netarsudil and latanoprostene bunod (LBN) -- greatly reduce intraocular pressure, with lasting results in various animal models of glaucoma and in humans.